Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Palantir stock surges as artificial-intelligence gains drive an earnings and revenue beat, China begins an antitrust probe ...

Wall Street rebounds as tech stocks surge, with the S&P 500 up 0.5% amid easing trade tensions and strong corporate earnings.

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Merck & Company (MRK – Research Report), with a ...

B ig moves for a couple of high-profile names masked a steady undercurrent of basically healthy earnings on Tuesday.

The stock markets in the US opened higher on February 4 as investors remained cautious about China’s stance on the Trump ...

Asian shares are trading mostly lower as markets mull the impact of tariffs being imposed by the United States and China ...

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange, ...

Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines.

BofA lowered the firm’s price target on Merck (MRK) to $112 from $118 and keeps a Buy rating on the shares. Q4 results were “decent,” but 2025 ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...